Lilly's EBGLYSS Delivers Positive Phase 3 Results in Pediatric Atopic Dermatitis, Paving Way for Label Expansion
LLY sits 58% above its 52-week low of $623.78.
Summary
Eli Lilly announced positive Phase 3 results for its drug EBGLYSS (lebrikizumab-lbkz) in treating moderate-to-severe atopic dermatitis in patients aged six months to 18 years. The trial demonstrated strong efficacy, with 63% achieving EASI-75 and 44% achieving IGA 0,1 at week 16, and a consistent safety profile. This positions EBGLYSS as the first and only selective IL-13 inhibitor to achieve such outcomes in this pediatric population. Lilly plans to submit this data for a potential label update to U.S. and global regulators, which would significantly expand the drug's market opportunity and bolster its dermatology pipeline. This positive development diversifies Lilly's growth drivers beyond its highly successful GLP-1 franchise.
At the time of this announcement, LLY was trading at $987.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $930.7B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.